Eli Lilly

Retatrutide investigational drug development and safety

4 clusters · 9 sources · last updated about 17 hours ago

Latest: Saudi FDA warns against unapproved use of Retatrutide

Retatrutide, an investigational synthetic peptide developed by Eli Lilly (also known by the code LY3437943), is being studied for its metabolic potential in managing food regulation, sugar, and weight. As a triple recept

Roche investment suspension in Germany

2 clusters · 26 sources · last updated about 20 hours ago

Latest: Roche suspends new investments in Germany

Swiss pharmaceutical company Roche has announced a temporary suspension of all future investment decisions in Germany. The company cited a significant loss of confidence in the German government’s healthcare policies as

Nvidia expands AI ecosystem and defends AI future

26 clusters · 569 sources · last updated 1 day ago

Latest: NVIDIA reports triple-digit revenue growth amid AI inflection point

In late July 2026, Nvidia deepened its control of the AI value chain through strategic investments, including a $500 billion memory deal with SK Hynix and a $5 billion stake in Safe Superintelligence. By late August, the

Hanmi Pharmaceutical obesity drug Epe/Effe launch

3 clusters · 10 sources · last updated 1 day ago

Latest: Hanmi Pharmaceutical to launch domestic obesity drug Effe

Hanmi Pharmaceutical is preparing to launch ‘Epe’ (also referred to as ‘Effe’), a domestically developed GLP-1 class obesity medication in South Korea. Having received approval as the country’s 45th new drug from the Min

Solana price volatility amid RWA growth and ETF inflows

45 clusters · 125 sources · last updated 1 day ago

Latest: Solana tokenized stock addresses reach 1.5 million milestone

Solana has transitioned from technical uncertainty toward significant institutional and ecosystem growth, though price volatility remains high. In August 2026, the SOL token broke above $100, supported by record-breaking

S&P 500 concentration and market divergence

7 clusters · 35 sources · last updated 2 days ago

Latest: AI investment returns remain concentrated among tech giants

The S&P 500 bull market remains heavily driven by artificial intelligence, with concentration reaching unprecedented levels. While the index has hit record highs, touching 7,844 points, growth is increasingly localized.

GLP-1 drugs: clinical trends, safety, and market shifts

314 clusters · 1159 sources · last updated 2 days ago

Latest: GLP-1 medications and weight management strategies

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Cardiovascular benefits rema

Brazil ANVISA expands product safety enforcement

43 clusters · 290 sources · last updated 2 days ago

Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

Novo Nordisk pivots strategy to counter patent cliff

112 clusters · 548 sources · last updated 2 days ago

Latest: Novo Nordisk faces intense competition in obesity drug market

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,

Songdo biotechnology cluster development

2 clusters · 10 sources · last updated 2 days ago

Latest: Incheon Mayor announces industrial vision to target 5% economic growth

Development of the Songdo bio-cluster in Incheon, South Korea, has progressed through major infrastructure and partnership initiatives. Construction began on the ‘K-Bio Lab Hub’ at the Yonsei University International Cam

Global bond yields surge amid debt risks and structural debt

39 clusters · 212 sources · last updated 4 days ago

Latest: European and US bond market strategies amid interest rate uncertainty

Global bond markets are experiencing a period of intense volatility and structural shifts, characterized by yields reaching multi-decade highs. In the United States, the 10-year Treasury yield has approached 5%, while th

Advancements in breast cancer treatment and diagnostics

4 clusters · 10 sources · last updated 4 days ago

Latest: Advances and access challenges in breast cancer care

Medical advancements in breast cancer management are increasingly focusing on personalized diagnostics and targeted therapies. Research from the OPTIMA study suggests the Prosigna genetic test may allow many women with e

Brazil SUS management, regulation, and service expansion

20 clusters · 127 sources · last updated 5 days ago

Latest: Brazil's SUS could lose R$ 300 billion over ten years

Brazilian health officials continue to expand the Unified Health System (SUS) through digital integration, specialized care, and legislative reforms. To improve resource management, the National Health Fund launched Inve

Novo Nordisk CagriSema clinical trial results

2 clusters · 7 sources · last updated 6 days ago

Latest: Novo Nordisk experimental drug CagriSema shows 25% weight loss in women

Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase

EMA recommendation for Eli Lilly obesity medication

2 clusters · 15 sources · last updated 8 days ago

Latest: Eli Lilly's Foundayo receives positive EMA recommendation for obesity and diabetes

The European Medicines Agency (EMA) has issued a positive recommendation via its Committee for Medicinal Products for Human Use (CHMP) for Eli Lilly’s oral medication, Foundayo (orforglipron). The drug is a small-molecul

Evolution of obesity medication treatments

3 clusters · 9 sources · last updated 10 days ago

Latest: Obesity research advances toward oral treatments

The landscape of obesity treatments is shifting toward more convenient delivery methods, specifically weekly injections and oral therapies. In the United States, Viking Therapeutics is preparing to begin phase 3 clinical

AI-driven drug discovery and regulatory integration

19 clusters · 57 sources · last updated 12 days ago

Latest: AI and robotics enter pharmaceutical quality control laboratories

By late 2026, the pharmaceutical industry has transitioned from pilot programs to full-scale execution, focusing on a ‘data closed loop’ through major partnerships such as Eli Lilly and NVIDIA, and Merck & Co., Inc. with

GLP-1 weight-loss drug market regulation in Africa

2 clusters · 5 sources · last updated 13 days ago

Latest: South Africa regulates weight-loss drug compounding amid rising black market

The market for GLP-1 weight-loss medications is expanding significantly across Africa, with South Africa serving as a primary hub. While the market has reached substantial valuations, the surge in demand has led to incre

FDA and UK authorization of Eli Lilly's Onswik insulin

3 clusters · 9 sources · last updated 14 days ago

Latest: Onswik weekly insulin authorized for type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection developed by Eli Lilly for adults with type 2 diabetes. Clinical data from the QWINT p

Solidigm potential US IPO

2 clusters · 16 sources · last updated 15 days ago

Latest: Isomorphic Labs seeks valuation up to $50 billion

Solidigm, a US-based subsidiary of SK hynix specializing in NAND and enterprise SSDs, is considering an initial public offering (IPO) in the United States as early as 2027. The potential listing could value the company a

WHO childhood obesity management guidelines

3 clusters · 67 sources · last updated 16 days ago

Latest: WHO issues first global guidelines for childhood obesity management

The World Health Organization (WHO) has released its first global guidelines for the integrated management of obesity in children and adolescents aged 0 to 19. This follows reports that obesity prevalence in this age gro

Eli Lilly retatrutide development and black market issues

11 clusters · 32 sources · last updated 16 days ago

Latest: Incretin agonists show potential in obesity treatment amid safety concerns

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

Biopharmaceutical manufacturing expansion in Songdo

3 clusters · 7 sources · last updated 16 days ago

Latest: South Korean biotech firms expand global presence and Japanese market reach

Biopharmaceutical manufacturing capacity is expanding within the Songdo Bio Cluster in South Korea. Celltrion has renewed its European Medicines Agency (EMA) Good Manufacturing Practice (EU-GMP) certification for its d

Sensory loss and voice changes as dementia risk factors

7 clusters · 19 sources · last updated 16 days ago

Latest: Visual impairment linked to higher dementia risk in long-term study

Research continues to identify sensory impairments, particularly hearing loss, as significant modifiable risk factors for dementia and cognitive decline. While hearing loss and dementia are distinct conditions, they are

Medical advancements and drug approvals in Italy

2 clusters · 23 sources · last updated 16 days ago

Latest: AIFA approves Mirikizumab reimbursement for Crohn's disease in Italy

Medical developments in Italy have recently focused on advancements in respiratory medicine and gastroenterology. During the XXVII National Congress of the Italian Society of Pulmonology (SIP/IRS) in Rome, experts discus

Eli Lilly therapeutic pipeline expansion

2 clusters · 3 sources · last updated 17 days ago

Latest: Eli Lilly expands research in dermatology and psychedelics

Eli Lilly has been pursuing strategic expansions into new therapeutic fields, specifically mental health, immunology, and dermatology. In September 2026, the company completed its acquisition of AtaiBeckley, a biopharmac

Eli Lilly EloraTZP obesity drug clinical trials

3 clusters · 21 sources · last updated 17 days ago

Latest: Eli Lilly trial shows EloraTZP combination boosts weight loss

Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data presented at the European Ass

Advancements in Alzheimer's detection, AI, and drug access

18 clusters · 83 sources · last updated 18 days ago

Latest: Dementia diagnosis and new drugs improve patient outlook

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator, studies suggest its predictive power in symptom-f

Sarcopenia Prevention and Muscle-Preserving Medical Trends

18 clusters · 58 sources · last updated 20 days ago

Latest: Strength training and protein intake recommended to combat muscle loss in aging adults

By early October 2026, medical focus has intensified on the management of sarcopenia, particularly regarding the nutritional complexities faced by patients with chronic kidney disease (CKD). While the general elderly pop

EASD diabetes congress in Milan

3 clusters · 49 sources · last updated 24 days ago

Latest: EASD 2026 in Milan showcases diabetes research and new medical technologies

The 62nd Congress of the European Association for the Study of Diabetes (EASD) in Milan highlighted significant advancements in diabetes management, screening, and therapeutic guidelines. Clinical discussions centered on